Lyme Disease Vaccine Candidate VLA15 Shows Antibodies 6 Months Post Completion

ContagionLive published the article “Lyme Disease Vaccine Shows Lyme disease vaccine candidateAntibodies 6 Months after Completion” by Senior Editor, John Parkinson, on December 1, 2022. The article provides details of the most recent investigational outcomes for Pfizer and Valneva’s Lyme disease vaccine candidate, VLA15.

Parkinson writes that results stemming from the most recent trial, which took place earlier this year, showed higher antibody levels in the three-dose vaccination schedule compared to the two-dose vaccination schedule. Trial participants included healthy adults as well as a pediatric cohort.

Similar to the previous clinical VLA15 studies, antibody levels decreased over time in all trial groups but stayed above baseline, as confirmed six months post-completion of both vaccination schedules. The companies state that this “investigational multivalent protein subunit vaccine” uses a demonstrated mechanism that targets the outer surface protein A (OspA) of Borrelia burgdorferi.

For more information:

Read the article on the ContagionLive website.

Read more about Lyme disease vaccines.